The estimated Net Worth of Craig C. Hopkinson is at least $7.55 Millón dollars as of 23 February 2024. Craig Hopkinson owns over 7,689 units of Alkermes plc stock worth over $3,005,678 and over the last 7 years he sold ALKS stock worth over $888,699. In addition, he makes $3,656,340 as Executive Vice President y Research and Development and Chief Medical Officer at Alkermes plc.
Craig has made over 19 trades of the Alkermes plc stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 7,689 units of ALKS stock worth $204,297 on 23 February 2024.
The largest trade he's ever made was exercising 29,008 units of Alkermes plc stock on 18 February 2022 worth over $770,743. On average, Craig trades about 7,038 units every 77 days since 2018. As of 23 February 2024 he still owns at least 113,123 units of Alkermes plc stock.
You can see the complete history of Craig Hopkinson stock trades at the bottom of the page.
Dr. Craig C. Hopkinson M.D. serves as Executive Vice President, Research and Development and Chief Medical Officer of the Company. Prior to assuming his current positions, Dr. Hopkinson was our Chief Medical Officer, and Senior Vice President of Medicines Development and Medical Affairs from February 2018 to January 2020, and our Chief Medical Officer and Senior Vice President of Clinical Development and Medical Affairs from May 2017 to February 2018. Prior to joining the Company, Dr. Hopkinson served as Senior Vice President of Clinical Development and Head of Global Medical Affairs at Vertex Pharmaceuticals Incorporated from July 2014 until May 2017. Prior to that, Dr. Hopkinson held various executive management positions at Eisai Pharmaceuticals, including President Eisai Value Maximization Systems from January 2013 to July 2014 and President and Chief Medical Officer of the Frontier Product Creation Unit from October 2011 to December 2012. Dr. Hopkinson has extensive experience in research and development, medical affairs, and interactions with the FDA.
As the Executive Vice President y Research and Development and Chief Medical Officer of Alkermes plc, the total compensation of Craig Hopkinson at Alkermes plc is $3,656,340. There are 1 executives at Alkermes plc getting paid more, with Richard Pops having the highest compensation of $14,637,100.
Craig Hopkinson is 51, he's been the Executive Vice President y Research and Development and Chief Medical Officer of Alkermes plc since 2020. There are 18 older and 3 younger executives at Alkermes plc. The oldest executive at Alkermes plc is Dr. Floyd E. Bloom M.D., 84, who is the Founder.
Craig's mailing address filed with the SEC is 850;852, Winter Street, Lincoln, Middlesex County, Massachusetts, 02451, United States.
Over the last 13 years, insiders at Alkermes plc have traded over $407,046,771 worth of Alkermes plc stock and bought 86,119 units worth $2,034,840 . The most active insiders traders include Corp Plc Elan Science Three..., Richard F Pops y James M Frates. On average, Alkermes plc executives and independent directors trade stock every 5 days with the average trade being worth of $1,083,232. The most recent stock trade was executed by David Joseph Gaffin on 3 August 2024, trading 2,014 units of ALKS stock currently worth $53,512.
alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (cns) diseases. the company has a diversified commercial product portfolio and a substantial clinical pipeline of product candidates for chronic diseases that include schizophrenia, depression, addiction and multiple sclerosis. headquartered in dublin, ireland, alkermes plc has an r&d center in waltham, massachusetts; a research and manufacturing facility in athlone, ireland; and a manufacturing facility in wilmington, ohio. for more information, please visit alkermes’ website at www.alkermes.com.
Alkermes plc executives and other stock owners filed with the SEC include: